Prof. Wenzhou Sun 孙文洲
Chief Physician, Professor
Department of Medical Oncology (II), Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for breast, lung, gastric, colorectal, liver cancers, malignant lymphoma, and soft tissue tumors. Focuses on chemotherapy, endocrine therapy, immunotherapy, targeted therapy, and anti-angiogenic treatment.
Dr. Sun graduated from Harbin Medical University in 1993, earning a master’s in oncology in 1999 and a PhD in 2007. Dr. Sun trained at the University of Pittsburgh Medical Center in 2007 and joined a postdoctoral station in 2009. As Chief Physician and Professor, Dr. Sun specializes in standardized and individualized medical oncology, particularly for breast cancer neoadjuvant and metastatic care, and manages malignant effusions.
Professional roles
- Member, Breast Cancer Professional Committee, Heilongjiang Anti-Cancer Association
- Member, Malignant Lymphoma Professional Committee, Heilongjiang Province
- Member, Oncology Professional Committee, Heilongjiang Rehabilitation Medical Association
- Standing Editorial Board Member, Chinese Journal of Medicine
Name order: in Chinese the family name comes first (Sun Wenzhou). Papers usually list the name as Wenzhou Sun or Sun W.
Selected publications
4 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (senior author): Retraction Note: Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study. PubMed 42571011
- Minerva Med, 2022 (senior author): Third-line therapy for HER2-positive advanced breast cancer: a case report. PubMed 35904376
- BMC Cancer, 2021 (senior author): Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study. PubMed 33632157
- Front Oncol, 2020 (first author): LRH1 Promotes Tumor Cell Proliferation and Migration and Is Correlated With Poor Prognosis in Ovarian Cancer. PubMed 33194722
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion